2022 SCIEX Biopharma meeting
September 27 and 28, 2022
Virtual event: 10:00 a.m. — 1:00 p.m. CET
Register now to secure your seat!
This online event has been designed for our customers and brings together opinion leaders, top scientists, and industry innovators to share their research in the biopharma field.
The technologies presented will be CE and LC-MS.
The presentations will also be available on demand after the virtual event.
| Time | Agenda |
|---|---|
| 10:00–10:10 | Welcome and introduction |
| 10:10–10:30 | My first date with BioPhase 8800 system - impressions from a research lab Dirk Schiroky, Merck |
| 10:30–11:00 | Tips and tricks for success in CE analysis Marcus Heinl, SCIEX |
| 11:00–11:20 | ZenoTOF 7600 system immunoglobulin peptide mapping on a robust and standardized LC platform Moritz Heusel, Evosep ApS |
| 11:20–11:50 | Host Cell Protein analysis in vaccines– using LC-MS technologies Thomas Kofoed, Alphalyse |
| 11:50–12:00 | Break |
| 12:00–12:20 | ZenoTOF 7600 system as a basic tool for development, manufacture and characterization Angela Fernandez, Leanbio Pro |
| 12:20–12:50 | Comprehensive assessment of glycosylation in recombinant proteins using a novel fragmentation technique Séverine Clavier, Sanofi France |
| 12:50–13:00 | Wrap up and final remarks |
| Time | Agenda |
|---|---|
| 10:00–10:10 | Welcome and introduction |
| 10:10–10:30 | Topic: use of CE in RNA vaccine production Simon Klenk, BioNTech |
| 10:30–11:00 | Tip and tricks for success in oligo analysis Cathy Lane, SCIEX |
| 11:00–11:20 | Validation and transfer of Influenza CE-Purity assay into QC Lab at Seqirus Patrick Buckley, Seqirus |
| 11:20–11:50 | Analytical Methods for the Characterization of RNA Charlotte Graham, CPI |
| 11:50–12:00 | Break |
| 12:00–12:20 | Expression and characterisation of SARS-CoV-2 spike and other glycoproteins to support the discovery of new therapeutic agents Rachel Rowlinson and Mark Abbott, Peak Proteins |
| 12:20–12:50 | Handle with care: Ensuring LNP quality for better genetic medicines Adam Crowe, Precision Nanosystems |
| 12:50–13:00 | Wrap up and final remarks |